Almirall

(IN BRIEF) Almirall’s new data highlights the alarming lack of awareness regarding actinic keratosis (AK), a common precancerous dermatological condition linked to sun exposure, with more than one-third of affected individuals unaware of its causes. The survey, conducted across Spain, … Read the full press release →

(IN BRIEF) A recent study conducted by researchers from the Universities of Bristol and Bath, King’s College London, and University Medical Center Utrecht highlights the concerning prevalence of repeat antibiotic prescriptions for respiratory tract infections (RTIs) within the same episode … Read the full press release →

(IN BRIEF) Almirall, a leading biopharmaceutical company specializing in medical dermatology, has reported its full-year 2023 financial results, showcasing a 4% year-on-year growth in net sales driven by the strong performance of its European Dermatology business. The company’s total EBITDA … Read the full press release →

(IN BRIEF) Almirall S.A., a leading pharmaceutical company specializing in medical dermatology, has finalized an exclusive license agreement with Novo Nordisk for the development and commercialization of NN-8828, an IL-21 blocking monoclonal antibody. This innovative treatment holds potential for various … Read the full press release →